Form 4: Vor Biopharma CFO Han Wook Choi Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Han Wook Choi, CFO of Vor Biopharma Inc., reports a transaction involving common stock related to tax withholding obligations.
Summary
- On May 1, 2025, Han Wook Choi, the Chief Financial Officer of Vor Biopharma Inc., reported a transaction involving the company's common stock.
- A total of 2,061 shares were disposed of at a price of $0.66 per share to satisfy tax withholding obligations related to the settlement of restricted stock units.
- Following the transaction, Choi directly owns 51,280 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a standard transaction for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is related to tax obligations of an executive.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of transaction involving common stock. |
| 05/02/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Beneficial Ownership, VOR, Vor Biopharma, Han Wook Choi, CFO, Tax Withholding, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.